The combination demonstrated antitumor activity in checkpoint-inhibitor-naïve SCCHN patients, and also induced objective responses in patients anticipated to have relatively limited responsiveness to pembrolizumab alone, including NSCLC with tumor PD-L1 expression <1% and checkpoint-inhibitor-refractory UC. The gene discussed is CD274; the disease is neoplasm.